Early MS drug may alter brain inflammation signals
NCT ID NCT04466150
Summary
This study examines whether starting the medication ocrelizumab very early after a first MS symptom changes markers of inflammation in the spinal fluid. It involves 30 newly diagnosed adults who will receive the drug every 6 months for 3 years. The goal is to see if early, strong treatment might lead to better long-term outcomes by reducing ongoing brain inflammation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California San Francisco
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.